ENGLISH | 中文
Pfizer China Establishes Regional Headquarters in Shanghai
  
Share :  
  • Shanghai    October 29, 2004

  •  
  • Pfizer China announced today Shanghai will be the home of its new regional headquarters and that the company has established a new entity in Shanghai, the Pfizer Investment Holding Company. With the required approvals from the Ministry of Commerce and the Shanghai Municipal Government, the newly founded Pfizer China Regional Headquarters will work to consolidate and integrate the resources of the company to further Pfizer's investment in the China market.

    Mr. Alan Taylor, Pfizer Pharmaceuticals Regional President for Asia, presided over the ceremony. "World-class cities attract world-class companies and that is why we are here," said Mr. Taylor. "China is an important part of Pfizer's global development strategy. We wanted an increased presence here and an entity to help us to expedite our investment, and that is the core mission of the new Regional Headquarters," Mr. Taylor added.

    Mr. Allan Gabor, Chairman and General Manager of Pfizer Investment Holding Co., emphasized, "We have said we are committed, and we are a company driven by putting action behind our words." Mr Gabor continued, "We appreciate all of the support given by the Shanghai Municipal Government in the establishment of our Regional Headquarters in Shanghai. Our intention is to play an even greater role in the development of the healthcare environment here."

    The new Regional Headquarters will be located at in the CITIC Square in the Jing'an District of Shanghai.

    Pfizer has long been committed to the development of healthcare in China since it first entered the market in the early 1980s. To date, Pfizer's business in China covers three sectors: Human and Animal Pharmaceuticals and Drug Delivery. Among those, Pfizer's investment for its pharmaceutical business alone has been over US$500 million. The company has state-of-the-art pharmaceutical facilities in Dalian, Suzhou and Wuxi, with over 1500 employees. In addition, the company's Dalian plant has grown to become a product supply point for Pfizer Global Manufacturing in the Asia-Pacific Region.

    Pfizer has launched more than 40 new products in China to address medical needs in the disease areas of cardiovascular, endocrinology, neuroscience, infectious disease, arthritis and inflammation, urology, ophthalmology and oncology. Seven of Pfizer's 10 products with global sales of more than US$1 billion have been marketed in China, namely, Lipitor, Norvasc, Celebrex, Viagra, Diflucan, Zithromax and Zoloft.

    An important role of the new investment company will be to facilitate new product entry into China. In the coming five years, Pfizer plans to launch another 15 new drugs in China, which are targeted at improving the lives of patients throughout China. Featured by outstanding profiles of efficacy and safety, Pfizer's medicines are widely prescribed and accepted by an increasing number of physicians and patients.

    Pfizer also plays an active role in the communities where it operates, and the company gets involved in such activities as health education, medical training, disease control, charitable donations and disaster relief. This year, the Forbes Chinese Version named Pfizer in the top three most philanthropic companies in the 2003 MNCs Charity Donation List in China. Until now, Pfizer China has sponsored various community programs with more than RMB50 million yuan.

    In Shanghai, Pfizer is involved with a Teen Healthcare Education Program together with Shanghai Pudong Social Worker Association. The company also works with the Shanghai Huashan Anti-infective Institute to guide physicians on the appropriate use of antibiotic medications. Furthermore, Pfizer will launch an Anti-Cancer Education Program with American Cancer Society (ACS), and in association with the Shanghai Drug Administration and the Shanghai Administration of Industry and Commerce. The global company recently also conducted Anti-Counterfeiting Training to protect Chinese patients the hazardous risk of counterfeit drugs.

    For more information, please contact Pfizer Investment Holding Co., Ltd.

    Corporate Affairs, 010 65880288

     


Text SizeAAA